Skip to main content

Articles

Page 2 of 5

  1. Percutaneous left atrial appendage occlusion (LAAO) has been rapidly evolving since FDA’s approval in 2015 and has become more of a same-day-discharge procedure. Cancer patient with atrial fibrillation/flutter...

    Authors: Yaqi Zhang, Zhuoran Yang, Muhammad U. Almani, Raquel Soon-Shiong and Bolun Liu
    Citation: Cardio-Oncology 2023 9:39
    Content type: Research Published on:

  2. Osimertinib is a third-generation epidermal growth factor receptor (EGFR) inhibitor that is currently the first-line treatment for metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) due to its favorabl...

    Authors: Karishma Patel, Kristie Y. Hsu, Kevin Lou, Krishan Soni, Yoo Jin Lee, Claire K. Mulvey and Alan H. Baik
    Citation: Cardio-Oncology 2023 9:38
    Content type: Case Report Published on:

    The Correction to this article has been published in Cardio-Oncology 2023 9:43

  3. Millions of cancer survivors are at risk of cardiovascular diseases, a leading cause of morbidity and mortality. Tools to potentially facilitate implementation of cardiology guidelines, consensus recommendatio...

    Authors: Sherry-Ann Brown, Abdulaziz Hamid, Erin Pederson, Allen Hanna BS, Ragasnehith Maddula, Rachel Goodman, Morgan Lamberg, Pedro Caraballo, Peter Noseworthy, Opeoluwa Lukan, Gift Echefu, Generika Berman and Indrajit Choudhuri
    Citation: Cardio-Oncology 2023 9:37
    Content type: Research Published on:

  4. To determine the impact of acute SARS-CoV-2 infection on patient with concomitant active cancer and CVD.

    Authors: Brijesh Patel, Scott A. Chapman, Jake T. Neumann, Aayush Visaria, Oluwabunmi Ogungbe, Sijin Wen, Maryam Khodaverdi, Priyal Makwana, Jasvinder A. Singh and George Sokos
    Citation: Cardio-Oncology 2023 9:36
    Content type: Research Published on:

  5. Antineoplastic monoclonal antibodies (mAbs), such as trastuzumab, bevacizumab, and pertuzumab have been the mainstay of therapy in cancer patients. Despite proven efficacy of the monoclonal antibodies, cardiov...

    Authors: Abdulrazaq S. Al-Jazairi, Nahlah Bahammam, Dhai Aljuaid, Lama Almutairi, Shroog Alshahrani, Norah Albuhairan, Peter M. B. Cahusac and Ghazwa B. Korayem
    Citation: Cardio-Oncology 2023 9:35
    Content type: Research Published on:

  6. Immune checkpoint inhibitor (ICI) myocarditis is associated with significant mortality risk. Electrocardiogram (ECG) changes in ICI myocarditis have strong prognostic value. However the impact of complete hear...

    Authors: Michael P. O’Shea, Suganya Arunachalam Karikalan, Ali Yusuf, Timothy Barry, Eiad Habib, John O’Shea, Michael Killian, Eman Baqal, Srishti Nayak, Rajeev Masson, Joerg Hermann, Shimoli Shah, Chadi Ayoub and Hicham El Masry
    Citation: Cardio-Oncology 2023 9:34
    Content type: Research Published on:

  7. Men diagnosed with prostate cancer are at risk for competing morbidity and mortality due to cardiometabolic disease given their advanced age at diagnosis, high prevalence of pre-existing risk factors, and rece...

    Authors: Andrew W. Hahn, Whittney Thoman, Efstratios Koutroumpakis, Amer Abdulla, Sumit K. Subudhi, Ana Aparicio, Karen Basen-Enngquist, Christopher J. Logothetis and Susan C. Gilchrist
    Citation: Cardio-Oncology 2023 9:33
    Content type: Research Published on:

  8. Baseline cardiovascular risk factors correction is recommended in all cancer patients undergoing potentially cardiotoxic therapies. Despite available guidelines, real-world data on dyslipidemia prevalence and ...

    Authors: Massimiliano Camilli, Irma Bisceglia, Maria Laura Canale, Fabio Maria Turazza, Leonardo De Luca, Domenico Gabrielli, Michele Massimo Gulizia, Fabrizio Oliva and Furio Colivicchi
    Citation: Cardio-Oncology 2023 9:32
    Content type: Correspondence Published on:

  9. Patients treated for hematologic malignancy often experience reduced exercise capacity and increased fatigue; however whether this reduction is related to cardiac dysfunction or impairment of skeletal muscle o...

    Authors: Justin M. Canada, John McCarty, Jennifer H. Jordan, Cory R. Trankle, Kevin DeCamp, Josh D. West, Mary Ann Reynolds, Rachel Myers, Katey Sweat, Virginia McGhee, Ross Arena, Antonio Abbate and W. Gregory Hundley
    Citation: Cardio-Oncology 2023 9:31
    Content type: Research Published on:

  10. Cancer survival rates have been steadily improving in the adolescent and young adult (AYA) population, but survivors are at increased risk for cardiovascular disease (CVD). The cardiotoxic effects of anthracyc...

    Authors: Jeannette R. Wong-Siegel, Robert J. Hayashi, Randi Foraker and Joshua D. Mitchell
    Citation: Cardio-Oncology 2023 9:30
    Content type: Research Published on:

  12. Carcinoid syndrome (CS) is a unique constellation of symptoms caused by release of vasoactive substances from neuroendocrine tumors (Pandit et al., StatPearls, 2022). Neuroendocrine tumors are rare with an ann...

    Authors: Aditi Sharma, Maria E. Fierro, Stella Pak, Keerthi Thallapureddy, Moyosore Awobajo, Dawn Hui and Prince Otchere
    Citation: Cardio-Oncology 2023 9:28
    Content type: Case Report Published on:

  14. 25% of all breast cancer patients have HER-2 overexpression. Breast Cancer patients with HER-2 overexpression are typically treated with HER-2 inhibitors such as Trastuzumab. Trastuzumab is known to cause a de...

    Authors: Prince Otchere, Olusola Adekoya, Samuel B. Governor, Naveen Vuppuluri, Akruti Prabhakar, Stella Pak, Oduro Oppong-Nkrumah, Francis Cook, Rudy Bohinc and Gregory Aune
    Citation: Cardio-Oncology 2023 9:26
    Content type: Research Published on:

  17. Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction.

    Authors: Matthew Dean, Min Jung Kim, Sharon Dimauro, Susan Tannenbaum, Garth Graham, Bruce T. Liang and Agnes S. Kim
    Citation: Cardio-Oncology 2023 9:23
    Content type: Research Published on:

  19. Many ca. survivors exhibit signs of IR, an important risk factor for the development of CAD. CAC scans offer a risk assessment of CV disease before cardiac damage has occurred. We investigated how IR affects C...

    Authors: N. Jacobi, S. Ortman, L. Buda and Daniel Duprez
    Citation: Cardio-Oncology 2023 9:21
    Content type: Research Published on:

  20. Despite the cardiotoxic effect of anthracycline on the left ventricle (LV) was totally identified. The assessment of the anthracycline effect on the right ventricle(RV) by conventional echocardiography was a c...

    Authors: Wafaa S. El-Sherbeny, Nesreen M. Sabry, Shaimaa B. El-Saied and Basma Elnagar
    Citation: Cardio-Oncology 2023 9:20
    Content type: Research Published on:

  21. Though the incidence of atrial fibrillation (AF) is increased in patients with cancer, the effectiveness of catheter ablation (CA) for AF in patients with cancer is not well studied.

    Authors: Sarju Ganatra, Sonu Abraham, Ashish Kumar, Rohan Parikh, Rushin Patel, Sumanth Khadke, Amudha Kumar, Victor Liu, Andrea Nathalie Rosas Diaz, Tomas G. Neilan, David Martin, Bruce Hook, Sourbha S. Dani, Aarti Asnani and Anju Nohria
    Citation: Cardio-Oncology 2023 9:19
    Content type: Research Published on:

  22. Chimeric antigen receptor T- Cell (CAR-T) immunotherapy has been a breakthrough treatment for various hematological malignancies. However, cardiotoxicities such as new-onset heart failure, arrhythmia, acute co...

    Authors: Dae Hyun Lee, Sanjay Chandrasekhar, Michael D. Jain, Rahul Mhaskar, Kayla Reid, Sae Bom Lee, Salvatore Corallo, Melanie J. Hidalgo-Vargas, Abhishek Kumar, Julio Chavez, Bijal Shah, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Christina Bachmeier, Rawan Faramand…
    Citation: Cardio-Oncology 2023 9:18
    Content type: Research Published on:

  23. Despite advances in chemotherapy, the drugs used in cancer treatment remain rather harmful to the cardiovascular system, causing structural and functional cardiotoxic changes. Positron-emission tomography asso...

    Authors: Mônica M. C. Becker, Gustavo F. A. Arruda, Diego R. F. Berenguer, Roberto O. Buril, Daniela Cardinale and Simone C. S. Brandão
    Citation: Cardio-Oncology 2023 9:17
    Content type: Review Published on:

  25. Immune checkpoint inhibitors (ICIs) are currently widely used for treatment of various types of cancers. ICI-induced myocarditis, though uncommon, accounts for high risk of major adverse cardiac events and mor...

    Authors: Khan O. Mohammad, Hanna Fanous, Sneha Vakamudi and Yan Liu
    Citation: Cardio-Oncology 2023 9:15
    Content type: Case Report Published on:

  26. Immune checkpoint inhibitor (ICI) myocarditis is associated with high morbidity and mortality. While endomyocardial biopsy (EMB) is considered a gold standard for diagnosis, the sensitivity of EMB is not well ...

    Authors: Jesus Jimenez, Nicolas Kostelecky, Joshua D. Mitchell, Kathleen W. Zhang, Chieh-Yu Lin, Daniel J. Lenihan and Kory J. Lavine
    Citation: Cardio-Oncology 2023 9:14
    Content type: Research Published on:

  27. Echocardiograms are recommended every 3 months in patients receiving human epidermal growth factor 2 (HER2)-targeted therapy for surveillance of left ventricular ejection fraction (LVEF). Efforts to tailor tre...

    Authors: Anthony F. Yu, Chau T. Dang, Justine Jorgensen, Chaya S. Moskowitz, Patricia DeFusco, Eric Oligino, Kevin C. Oeffinger, Jennifer E. Liu and Richard M. Steingart
    Citation: Cardio-Oncology 2023 9:13
    Content type: Research Published on:

  28. This study aimed to evaluate the association between preoperative hs-cTnI and long-term mortality and major adverse cardiovascular events (MACE) in colorectal cancer patients.

    Authors: Yitao Zhang, Zicheng Huang, Sutian Hu, Jinhong Si, Shiyao Cheng, Zhichong Chen, Jiaojie Xue, Xue Lou, Huajing Peng, Zequan Li, Mao Ouyang, Xiang Gao and Weijie Zeng
    Citation: Cardio-Oncology 2023 9:12
    Content type: Research Published on:

  29. Arterial occlusive events are an emerging problem in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) therapy. Endothelial cell damage is thought to play an important role...

    Authors: Tomohiro Kaneko, Sakiko Miyazaki, Azusa Kurita, Ryoko Morimoto, Shun Tsuchiya, Naoki Watanabe, Tomoiku Takaku, Norio Komatsu and Tohru Minamino
    Citation: Cardio-Oncology 2023 9:11
    Content type: Research Published on:

  30. Cancer patients receiving chemotherapy have an increased risk of cardiovascular complications. This limits the widespread use of lifesaving therapies, often necessitating alternate lower efficacy regimens, or ...

    Authors: Ali Mir, Yasra Badi, Seif Bugazia, Anas Zakarya Nourelden, Ahmed Hashem Fathallah, Khaled Mohamed Ragab, Mohammed Alsillak, Sarah Makram Elsayed, Abdulrahman Ibrahim Hagrass, Sawyer Bawek, Mohamad Kalot and Zachary L. Brumberger
    Citation: Cardio-Oncology 2023 9:10
    Content type: Review Published on:

  31. Prostate cancer has a very high prevalence among elder men, and this could potentially increase as longevity in many parts of the world is increasing. Early stages of prostate cancer can have surgical options,...

    Authors: Aswini Kumar, Aswanth Reddy and Arjun Sekar
    Citation: Cardio-Oncology 2023 9:9
    Content type: Case Report Published on:

  32. Several cohort studies aimed at demonstrating an increased risk of cancer incidence and mortality in patients with a pre-existing diagnosis of heart failure (HF); however, conflicting results have been reporte...

    Authors: Massimiliano Camilli, Juan Guido Chiabrando, Marco Lombardi, Marco Giuseppe Del Buono, Rocco Antonio Montone, Antonella Lombardo, Filippo Crea and Giorgio Minotti
    Citation: Cardio-Oncology 2023 9:8
    Content type: Research Published on:

  33. The many improvements in cancer therapies have led to an increased number of survivors, which comes with a greater risk of consequent/subsequent cardiovascular disease. Identifying effective management strateg...

    Authors: Sherry-Ann Brown, Brian Y. Chung, Krishna Doshi, Abdulaziz Hamid, Erin Pederson, Ragasnehith Maddula, Allen Hanna, Indrajit Choudhuri, Rodney Sparapani, Mehri Bagheri Mohamadi Pour, Jun Zhang, Anai N. Kothari, Patrick Collier, Pedro Caraballo, Peter Noseworthy and Adelaide Arruda-Olson
    Citation: Cardio-Oncology 2023 9:7
    Content type: Research Published on:

  34. Acute myocardial infarction (AMI) and cancer are diseases with high morbidity and mortality worldwide, bringing a serious economic burden, and they share some risk factors. The purpose of this study was to det...

    Authors: Jianfeng Ye, Luming Zhang, Jun Lyu, Yidan Wang, Shiqi Yuan, Zhifeng Qin, Yu Liu, Tao Huang, Jinwei Tian and Haiyan Yin
    Citation: Cardio-Oncology 2023 9:6
    Content type: Research Published on:

  35. Consensus guidelines recommend periodic screening for coronary artery disease (CAD) in Hodgkin lymphoma (HL) survivors treated with radiation therapy (RT) to the chest. However, the prognostic utility of scree...

    Authors: Sanjay Divakaran, Diana M. Lopez, Sean M. Parks, Jon Hainer, Andrea K. Ng, Ron Blankstein, Marcelo F. Di Carli and Anju Nohria
    Citation: Cardio-Oncology 2023 9:5
    Content type: Research Published on:

  36. Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML). While the HMA decitabine, in its ...

    Authors: Ankur Sheel, Junu Bae, Ashlee Asada, Gregory A. Otterson, Ragavendra R. Baliga and Kristin L. Koenig
    Citation: Cardio-Oncology 2023 9:4
    Content type: Research Published on:

  37. Cardiac hemangiomas are very rare benign cardiac tumors. They can present at any age and clinical presentation varies according to location and size. We encountered an 87-year-old woman with a left atrial hema...

    Authors: Leart Berdica, Erisa Kola, Daniela Nakuci, Edlira Horjeti and Mehdi Alimehmeti
    Citation: Cardio-Oncology 2023 9:3
    Content type: Case Report Published on:

  38. Cancer survivors with prior chest radiation therapy (CXRT) frequently present with atrial fibrillation, heart failure, and have higher overall long-term mortality. There are no data examining the utility of le...

    Authors: Meer R. Zafar, Ashutosh Sharma, Sunitha Shyam Sunder, Badri Karthikeyan, Makoto Nagahama, Andrew Atia, Ronak Bahuva, Saraswati Pokharel, Vijay Iyer, Sharma Kattel and Umesh C. Sharma
    Citation: Cardio-Oncology 2023 9:2
    Content type: Research Published on:

  39. There is limited data on the impact of cardiac disease on long term outcomes of allogeneic stem cell transplant (alloSCT). Our study aims to describe the incidence of late cardiac events after alloSCT, identif...

    Authors: Christine Auberle, Daniel Lenihan, Feng Gao and Amanda Cashen
    Citation: Cardio-Oncology 2023 9:1
    Content type: Research Published on:

  40. Immune checkpoint inhibitors (ICI) are associated with immune-mediated adverse effects, potentially involving any organ. ICI has also been associated with an increased risk of cardiovascular disease in cancer ...

    Authors: Charlie Wang, Sophia Zoungas, Mabel Yan, Rory Wolfe, Andrew Haydon, Mark Shackleton, Mark Voskoboynik, Maggie Moore, Miles C. Andrews, Stephen J. Nicholls and Victoria Mar
    Citation: Cardio-Oncology 2022 8:23
    Content type: Research Published on:

  41. Paclitaxel-induced cardiac ischemia is a rare but life-threatening complication. Although it may be difficult to distinguish from hypersensitivity or infusion reactions, it should not be overlooked. We herein ...

    Authors: Shota Higami, Yusuke Tanaka, Tomomi Deguchi, Mariko Shiraishi and Yasuhiko Shiki
    Citation: Cardio-Oncology 2022 8:22
    Content type: Correspondence Published on:

  42. The full range of cardiovascular complications related to the use of Immune checkpoint inhibitors (ICI) is not fully understood. We aim to describe the spectrum of cardiovascular adverse events (cvAEs) by pres...

    Authors: Maria Sol Andres, Sivatharshini Ramalingam, Stuart D. Rosen, John Baksi, Rajdeep Khattar, Yulia Kirichenko, Kate Young, Nadia Yousaf, Alicia Okines, Robert Huddart, Kevin Harrington, Andrew J.S. Furness, Samra Turajlic, Lisa Pickering, Sanjay Popat, James Larkin…
    Citation: Cardio-Oncology 2022 8:21
    Content type: Research Published on:

  44. We report the case of a 59-year-old female patient with no previous cardiovascular disease treated for Breast cancer with Capecitabine. Shortly after starting treatment, she developed recurrent angina. An exer...

    Authors: George B. Strobel, Shiva P. Ponamgi, Attila Roka and Ahmed S. A. Aboeata
    Citation: Cardio-Oncology 2022 8:19
    Content type: Case Report Published on:

  45. Neo(adjuvant) systemic treatment regimens containing anthracyclines such as doxorubicin cause a significant risk of heart failure. These regimens are one of the corner stones of osteosarcoma treatment, and the...

    Authors: Julius C. Heemelaar, Jeroen Janson, Jerry Braun, Frank M. Speetjens, Michiel A. J. van de Sande, Juan D. V. Hugo, Daniela Q. C. M. Barge-Schaapveld, Saskia L. M. A. Beeres, Laurens F. Tops, Hans Gelderblom and M. Louisa Antoni
    Citation: Cardio-Oncology 2022 8:18
    Content type: Correspondence Published on:

  46. Cancer chemotherapy using anthracyclines is associated with cardiotoxicity (CTX), and left ventricular ejection fraction (LVEF) analysis is not sensitive to early cardiotoxic changes. Left ventricular global l...

    Authors: Diogo Pereira Santos Sampaio, João Batista Masson Silva, Daniela do Carmo Rassi, Aguinaldo F. Freitas Jr and Salvador Rassi
    Citation: Cardio-Oncology 2022 8:17
    Content type: Research Published on:

  47. Breast cancer patients are at a particularly high risk of cardiotoxicity from chemotherapy having a detrimental effect on quality-of-life parameters and increasing the risk of mortality. Prognostic biomarkers ...

    Authors: Cameron Brown, Michael Mantzaris, Elpiniki Nicolaou, Georgia Karanasiou, Elisavet Papageorgiou, Giuseppe Curigliano, Daniela Cardinale, Gerasimos Filippatos, Nikolaos Memos, Katerina K. Naka, Andri Papakostantinou, Paris Vogazianos, Erietta Ioulianou, Christos Shammas, Anastasia Constantinidou, Federica Tozzi…
    Citation: Cardio-Oncology 2022 8:16
    Content type: Review Published on:

  49. Dedicated cardio-oncology services are emerging rapidly around the world in order to provide cardiovascular care (CV) for cancer patients. The perspectives of patients regarding their experience of cardiac sur...

    Authors: Jennifer White, Julie Byles, Trent Williams, Rossana Untaru, Doan T. M. Ngo and Aaron L. Sverdlov
    Citation: Cardio-Oncology 2022 8:14
    Content type: Research Published on:

  50. Reports of cardiac adverse events from oncology clinical trials often are at variance with reports derived from clinical observations or data-base reviews. These differences may lead to confusion, as different...

    Authors: Michael S. Ewer and Jay Herson
    Citation: Cardio-Oncology 2022 8:13
    Content type: Review Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 3.2
    5-year Journal Impact Factor: N/A
    Source Normalized Impact per Paper (SNIP): 0.822
    SCImago Journal Rank (SJR): 0.958

    Speed 2023
    Submission to first editorial decision (median days): 16
    Submission to acceptance (median days): 127

    Usage 2023
    Downloads: 302,427
    Altmetric mentions: 315

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Cardio-Oncology

ISSN: 2057-3804

Contact us